Research on the exoerythrocytic (EE) stages of human malaria parasites has been hindered because of the lack of an easily available suitable animal model. We report here an approach to produce mature EE-stage Plasmodium falciparum parasites by using severe combined immunodeficient (scid) mice with transplanted human hepatocytes. Transplantation of human hepatocytes into scid mice (scid hu-hep), their subsequent intravenous infection with P. fakiparum sporozoites, and the development of mature liver-stage merozoites was achieved. Plasmodium falciparum has a complex life cycle involving intracellular and extracellular stages in both the human host and the mosquito vector. Among the different developmental stages of P. falciparum, least is known about the hepatic or exoerythrocytic (EE) phase. This stage is a link between the extracellular sporozoite, inoculated by the mosquito vector, and the blood stage, which is responsible for producing disease. Both sporozoite and blood-stage parasites have been extensively studied because, in part, methods for blood-stage cultivation (1) and sporozoite production have been developed. The study of EE-stage parasites has been severely hampered by lack of a suitable in vitro or in vivo model, but it has been facilitated by development of in vitro culture techniques (2). Although the in vitro model is easily manipulable, it is characterized by a low infection rate (0.02-0.05%) (2, 3) and culture parameters that may not mimic in vivo conditions. While nonhuman primates, and in particular chimpanzees, have provided in vivo experimental models for the human malaria EE stage (3), their use has been difficult because of economic/ethical considerations and a limited supply. Development of a more convenient in vivo model would eliminate some of the difficulties associated with current in vitro and in vivo models.
Plasmodium falciparum has a complex life cycle involving intracellular and extracellular stages in both the human host and the mosquito vector. Among the different developmental stages of P. falciparum, least is known about the hepatic or exoerythrocytic (EE) phase. This stage is a link between the extracellular sporozoite, inoculated by the mosquito vector, and the blood stage, which is responsible for producing disease. Both sporozoite and blood-stage parasites have been extensively studied because, in part, methods for blood-stage cultivation (1) and sporozoite production have been developed. The study of EE-stage parasites has been severely hampered by lack of a suitable in vitro or in vivo model, but it has been facilitated by development of in vitro culture techniques (2) . Although the in vitro model is easily manipulable, it is characterized by a low infection rate (0.02-0.05%) (2, 3) and culture parameters that may not mimic in vivo conditions. While nonhuman primates, and in particular chimpanzees, have provided in vivo experimental models for the human malaria EE stage (3) , their use has been difficult because of economic/ethical considerations and a limited supply. Development of a more convenient in vivo model would eliminate some of the difficulties associated with current in vitro and in vivo models.
The characterization of severe combined immunodeficient (scid) mice has provided investigators with a model suitable for the study of many human diseases (4, 5) . The scid mouse lacks functional B and T cells; therefore, xenografts of human tissues can be successfully transplanted and maintained without rejection (6, 7) . We report here the successful transplantation of human hepatocytes into scid mice (designated scid hu-hep), their subsequent i.v. infection with P. falciparum (NF54) sporozoites, and development of mature liver-stage merozoites.
MATERIALS AND METHODS Mice. C.B-17/Icr scid/scid mice, originally obtained from Leonard Schultz (The Jackson Laboratories, Bar Harbor, ME), were bred at the University of Maryland at Baltimore animal facility and housed in microisolator cages. The animals were cared for and used strictly in accordance with the Public Health Service guidelines (8) .
Human Hepatocytes. Hepatocytes were prepared by collagenase digestion of human liver obtained from surgical resections or immediate autopsies (9) . Briefly, liver tissue was minced, washed with phosphate-buffered saline/EGTA repeatedly, and digested with collagenase (0.05%). Isolated hepatocytes were washed in Williams' medium containing 10%6 fetal calf serum, and their viability was determined by trypan blue exclusion. In some cases, cells were maintained overnight in Hanks' balanced salt solution containing a high glucose concentration without Ca2' or Mg2' at 40C (10) or were cultured on collagen-coated 35-mm Petri dishes before transplantation. Cultured hepatocytes were released from the collagen substratum by trypsin/collagenase treatment (11) . Both cold (40C) stored cells and cultured cells were centrifuged over a Nycodenz cushion to remove dead cells (12 1 . §To whom reprint requests should be addressed.
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9 days after injection with sporozoites. Kidney, liver, and spleen tissue were removed and processed for routine histology or cryosectioning. Frozen sections were examined with a panel of monoclonal and polyclonal antibodies specific for sporozoite or merozoite antigens. Direct fluorescent assay was undertaken with a monoclonal antibody (mAb 2A10, directly conjugated to fluorescein isothiocyanate), specific for the P. falciparum circumsporozoite (CS) protein (13) . Indirect immunofluorescent assays (IFAs) were done with mAbs 7H10, 7B2, and 3B10 (specific for merozoite surface antigen 1; MSA-1) (14), polyclonal antiserum against liver schizont antigen 1 (LSA-1) (15), or human anti-liver schizonts antibody (16) . Several other mAbs (8B7, 3D5, and 5E3) (17, 18) with specificities for blood-stage antigens were also used in IFAs against the collected tissues. Giemsa staining for the presence of infected hepatocytes was also done on some sections without prior immunofluorescent staining. In addition, sections were stained for the presence of human albumin with an anti-human albumin mAb and the avidin-biotin complex method (19) .
Passive mAb Transfer. To demonstrate one practical application of the scid hu-hep mouse, a passive transfer experiment using anti-CS mAb was undertaken. Six weeks after human hepatocyte transplant, five mice received 2.5 mg of anti-P. falciparum CS mAb (Pf 49 1B2.2) (13) and four mice received 2.5 mg of anti-P. vivax CS mAb (PvNVS 3) (20) i.p.
Proc. Natl. Acad. Sci. USA 89 (1992) Six hours later, each mouse was injected in the tail vein with 1.8 x 104 viable P. falciparum salivary gland sporozoites. Mice were sacrificed from both antibody-treated groups 24 hr and 7 days postinfection. The tissues were cryosectioned and stained by IFA and with Giemsa as detailed above to visualize infected hepatocytes. The number of EE schizonts in a minimum of five nonserial tissue sections (separated from each other by 100 gm) from each animal were counted. The mean number of schizonts per section was determined and significance was assessed by paired t test.
RESULTS AND DISCUSSION Transplantation of human hepatocytes under the kidney capsule produced a well-defined mass of cells (when viewed microscopically) that was easily sampled and very distinct, as compared to the kidney tissue, when examined using routine histological stains (Fig. 1) . In general, the hepatocytes distributed circumferentially under the capsule at the site of injection. In addition, immunohistochemical staining of the transplanted hepatocytes, with an anti-human albumin mAb, demonstrated albumin production in the hepatocytes for at least 3 weeks posttransplantation (data not shown), suggesting normal hepatocyte function (21 (Fig. 2) . Infected hepatocytes were limited to the area under the capsule containing the transplanted cells, with no parasites being found in the cortex or medulla of the mouse kidney. Other tissues-e.g., nontransplanted kidney, spleen, and liverwere negative when stained for parasites using mAb 2A10, suggesting efficient recognition and invasion of the implanted human hepatocytes by the inoculated sporozoites. Sections probed with an unrelated mAb (anti-Plasmodium bergei CS) or scid hu-hep kidney sections from mice that received the contents of uninfected mosquito salivary glands served as negative controls and did not contain any positively fluorescing cells (data not shown).
The intensity of the staining with mAb 2A10 decreased after 48 hr and was much less intense 72 hr after infection. This finding is consistent with earlier reports about the fate of CS protein in older EE schizonts (16, 22) . The mAb used was specific for CS protein and therefore was not a suitable probe for the later stages of the liver schizonts. Several other reagents [mAbs 7H10, 7B2, and 3B10 (generous gifts from Jeffrey Lyon) and polyclonal antiserum against LSA-1 (gift of Michael Hollingsdale)] were used to stain frozen sections collected 7, 8, and 9 days postinfection. mAbs 7H10, 7B2, and 3B10 react with an epitope on a polymorphic 195-kDa glycoprotein (MSA-1) found on both liver and blood-stage merozoites (23) . Polyclonal antisera to LSA-1 reacts very strongly with EE-stage parasites. An IFA using mAb 7H10 demonstrated the presence of MSA-1 on the parasites within the infected hepatocytes at 7, 8 (Fig. 3 Upper), and 9 days postinfection, although there was no apparent difference in the intensity of the staining among these time points. Similar results were obtained when the antisera to LSA-1 was used for IFA (Fig. 3 Subsequent Giemsa staining of antibody-probed frozen sections, and others not stained for IFA, revealed schizonts containing well-developed mature merozoites in the infected hepatocytes (Fig. 4) have been found to be permissive to infection with P. falciparum for up to 4 months after hepatocyte transplantation. These results indicate that hepatocytes from one source can be transplanted over a period of several days and then maintained in the mouse, optimizing the use of human liver The results of the passive transfer experiment demonstrated the capacity of mAb Pf 1B2.2 to decrease the number of infected hepatocytes as compared to the anti-Plasmodium vivax CS control. The number of EE schizonts in the anti-P. falciparum CS mAb-treated mice was significantly (P < 0.001) lower than the controls treated with the anti-P. vivax CS mAb (Fig. 5) . In addition, preliminary morphometric analysis of the sections suggests a significant difference in the size of the schizonts in the two groups, with the anti-P. falciparum group having the smaller EE-stage schizonts (data not shown). This in vivo model for the EE stage of the human malaria parasite is being further evaluated with regard to quantitation of sporozoite rate of infection and how it relates to current chimpanzee in vivo and human in vitro models. Nonetheless, it does demonstrate that infection of transplanted human hepatocytes by P. falciparum sporozoites and their subsequent schizogony can be achieved in a small animal model. Based on our studies to date, the scid hu-hep model is comparable to the results recently published (3), using the chimpanzee model, regarding the level of infection, maturity of EE forms, and production of infectious merozoites (data not shown). Although the lack of quantitative data makes it difficult to assess overall infection rates, the number of schizonts in P. falciparum-infected scid hu-hep kidney was determined that the differences between the anti-P. falciparum (anti-P.f. ab) and anti-P. vivax (anti-P.v. ab) mAb-treated mice, at both 24 hr and 7 days, were significant at P < 0.001. routinely -20 per section (Fig. 5, day 7) . The size of the mature EE schizonts varies between 20 and 67 gm in the scid mouse model at 7 days, larger than in vitro infected human hepatocytes (2) but consistent with other in vivo systems (3, (24) (25) (26) .
Nonhuman primate models currently being used have been valuable in the study of the malaria parasite, but these animals are increasingly rare and expensive to use in biomedical research (27) . The scid hu-hep has the potential for decreasing the need for nonhuman primates for the assessment of anti-EE-stage chemotherapeutic agents and candidate vaccines and making the use ofhuman liver feasible. The scid hu-hep mouse represents a model with a well-defined inbred genetic background. Groups of mice with transplanted hepatocytes would be genetically identical and as such would not be prone to the confounding effects of genetic variability. Furthermore, the model could be used to evaluate the potential for reagents developed for malaria prevention or control, for immunologic and biochemical characterization of liver stage antigens, and as an in vivo model to study the effect of activated immune cells and soluble factors on liver-stage parasites.
